Join Rob Gelissen at the 12th Global Drug Delivery & Formulation Virtual Summit

In this session, attendees will learn about:

  • Injection volumes of 2mL are becoming more common, but USP standards limit particle counts to a quantity per injection
  • Impact of higher concentrations biologics and concern for aggregation in presence of silicone
  • Floaters, inflammation, interocular pressure increases and silicone presence in injections
  • Impact of aging and changing injection profiles, resulting in slower or stalled autoinjector injections

Register to attend the virtual event: https://www.ddfevent.com/